InMed Pharmaceuticals (INM) Income from Non-Controlling Interests (2024 - 2025)
InMed Pharmaceuticals' (INM) quarterly Income from Non-Controlling Interests came in at $20000.0 in Q2 2025, down 94.31% quarter-over-quarter from $351549.0 in Q4 2024.
InMed Pharmaceuticals (INM) Income from Non-Controlling Interests (2024 - 2025) Analysis & Trends
InMed Pharmaceuticals' Income from Non-Controlling Interests history runs 2 years deep, the most recent figure standing at $20000.0 for Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.46 Bn | 87.60 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.95 Bn | 32.21 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.69 Bn | 30.75 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.61 Bn | 23.55 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 23.21 Bn | 21.06 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.32 Bn | 18.51 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.84 Bn | 16.53 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | InMed Pharmaceuticals | 7.04 Mn | 1.80 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 20,000.00 |
| Dec 31, 2024 | 351,549.00 |